Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 474

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 474
---
 LP, (iii) 75,983 NLS Common Shares held by BIOTECHNOLOGY VALUE FUND, L.P., (iv) 75,983 NLS Common Shares issuable upon exercise of pre -fundedwarrants exercisable within 60 days of May 28, 2025, held by BVF I GP LLC, (ii) 58,731 NLS Common Shares issuable upon exercise of pre -fundedwarrants exercisable within 60 days of May 28, 2025, held by BVF II GP LLC, (iii) 6,677 NLS Common Shares issuable upon exercise of pre -fundedwarrants exercisable within 60 days of May 28, 2025, held by BVF Partners OS Ltd., (iv) 2,287 NLS Common Shares issuable upon exercise of pre -fundedwarrants exercisable within 60 days of May 28, 2025, held by BVF Partners L.P. The address for Biotechnology Value Fund, or BVF, is 44 Montgomery Street, 40 thFloor, San Francisco, CA 94104, Mark N. Lampert is the President of BVF, Inc., the General Partner of BVF Partners L.P., and holds voting and dispositive power over the securities held by BVF. 273

Security Ownership of Certain Beneficial Owners and Management of Kadimastem before the Merger The following tables sets forth information regarding the beneficial ownership of Kadimastem Ordinary Shares as of May28, 2025 by: •each person known by Kadimastem to be the beneficial owner of 5% or more of Kadimastem’s outstanding Ordinary Shares before the consummation of the Merger; •each of its executive officers and directors; •all of its executive officers and directors as a group. Unless otherwise indicated, Kadimastem believes that all persons named in the table will have, immediately before the consummation of the Merger, sole voting and investment power with respect to all Kadimastem’s securities beneficially owned by them. Subject to the paragraph above, percentage ownership of issued shares is based on 4,603,668 Kadimastem Ordinary Shares issued and outstanding on a fully diluted basis as of May 28, 2025 (including an outstanding Kadimastem convertible loan that will be converted prior to the Closing).

| Name and Address of Beneficial Owner            |     | NLS